Skip to content

Medicale Corp.: 10-Q filed 2025-05-15

What Medicale Corp. reported in its quarterly report filed 2025-05-15 (fiscal Q2 2025): 24 published measures, 76 facts as tagged in accession 0001683168-25-003660.

This filing

Form
10-Q (quarterly report)
Filed
2025-05-15
Fiscal period
fiscal Q2 2025
Accession
0001683168-25-003660 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Medicale Corp. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-03-310USD
At 2024-09-30159USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2025-03-31123,888USD
At 2024-09-3099,092USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-03-31-123,888USD
At 2024-12-31-115,613USD
At 2024-09-30-98,933USD
At 2024-03-31-71,591USD
At 2023-12-31-60,027USD
At 2023-09-30-40,720USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-01-01 to 2025-03-31-8,275USD90
2024-10-01 to 2025-03-31-24,955USD182
2024-10-01 to 2024-12-31-16,680USD92
2024-01-01 to 2024-03-31-11,564USD91
2023-10-01 to 2024-03-31-30,871USD183
2023-10-01 to 2023-12-31-19,307USD92

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2024-10-01 to 2025-03-31-14,530USD182
2023-10-01 to 2024-03-31-58,788USD183

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2024-10-01 to 2025-03-3114,371USD182
2023-10-01 to 2024-03-3158,788USD183

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-03-31-200,800USD
At 2024-09-30-175,845USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2025-01-01 to 2025-03-315,920,000shares90
2024-10-01 to 2025-03-315,920,000shares182
2024-01-01 to 2024-03-315,920,000shares91
2023-10-01 to 2024-03-315,920,000shares183

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2025-01-01 to 2025-03-315,920,000shares90
2024-10-01 to 2025-03-315,920,000shares182
2024-01-01 to 2024-03-315,920,000shares91
2023-10-01 to 2024-03-315,920,000shares183

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2025-01-01 to 2025-03-310USD/shares90
2024-10-01 to 2025-03-310USD/shares182
2024-01-01 to 2024-03-310USD/shares91
2023-10-01 to 2024-03-31-0.01USD/shares183

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2025-01-01 to 2025-03-310USD/shares90
2024-10-01 to 2025-03-310USD/shares182
2024-01-01 to 2024-03-310USD/shares91
2023-10-01 to 2024-03-31-0.01USD/shares183

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2025-01-01 to 2025-03-310USD90
2024-10-01 to 2025-03-310USD182
2024-01-01 to 2024-03-310USD91
2023-10-01 to 2024-03-310USD183

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2025-01-01 to 2025-03-31-6,269USD90
2024-10-01 to 2025-03-31-21,264USD182
2024-01-01 to 2024-03-31-10,603USD91
2023-10-01 to 2024-03-31-29,910USD183

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-03-310USD
At 2024-09-30159USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2025-03-3125,932USD
At 2024-09-3015,507USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2025-01-01 to 2025-03-316,269USD90
2024-10-01 to 2025-03-3121,264USD182
2024-01-01 to 2024-03-3110,603USD91
2023-10-01 to 2024-03-3129,910USD183

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-03-315,920,000shares
At 2024-09-305,920,000shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2025-03-310USD
At 2024-09-30159USD
At 2024-03-31159USD
At 2023-09-30159USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2025-03-3176,320USD
At 2024-09-3076,320USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2025-01-01 to 2025-03-31-8,275USD90
2024-10-01 to 2025-03-31-24,955USD182
2024-01-01 to 2024-03-31-11,564USD91
2023-10-01 to 2024-03-31-30,871USD183

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2025-01-01 to 2025-03-316,269USD90
2024-10-01 to 2025-03-3121,264USD182
2024-01-01 to 2024-03-3110,603USD91
2023-10-01 to 2024-03-3129,910USD183

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2024-10-01 to 2025-03-310USD182
2023-10-01 to 2024-03-310USD183

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2024-10-01 to 2025-03-310USD182
2023-10-01 to 2024-03-310USD183

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2024-10-01 to 2025-03-316,894USD182
2023-10-01 to 2024-03-31-7,437USD183

Inspect the source

Entity
Medicale Corp. / CIK 0001827855
Captured
2026-09-21T17:29:16.444Z
SEC response SHA-256
c1f445f920afa9d1c1c35536b1c05f4f9bb3f99ac77fa8714c14eef1646836f4

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001827855.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))